Considering the published encouraging pCR rates by CRT combined with nivolumab in PD-L1 TPS-positive rectal cancer patients, a sequential therapeutic approach with CRT aiming at upregulating PD-L1 followed by the application of immune-checkpoint blockade might be interesting for initially PD-L1 TPS-negative tumors. Here, CD274 is linked to rectal cancer.